Patent ID: 11926619
Assignee: EISAI R&D MANAGEMENT CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 17:
18. A method of treating a subject having or suspected of having a neoplastic disorder, comprising administering to the subject a therapeutically effective amount of a compound and/or pharmaceutically acceptable salt according to any one of claims 1, 5, 6, 8, 9, and 10, or a pharmaceutical composition comprising a compound and/or pharmaceutically acceptable salt according to any one of claims 1, 5, 6, 8, 9, and 10, wherein administration of the compound and/or pharmaceutically acceptable salt, or pharmaceutical composition, induces at least one neoantigen and/or a T-cell response; wherein the neoplastic cell is derived from a cancer and the cancer is chosen from myelodysplastic syndrome, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, colon cancer, pancreatic cancer, endometrial cancer, ovarian cancer, breast cancer, uveal melanoma, gastric cancer, cholangiocarcinoma, and lung cancer.